108 related articles for article (PubMed ID: 7725847)
1. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon.
Vallisa D; Cavanna L; Berté R; Merli F; Ghisoni F; Buscarini L
Acta Haematol; 1995; 93(1):31-5. PubMed ID: 7725847
[TBL] [Abstract][Full Text] [Related]
2. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors.
Rönnblom LE; Alm GV; Oberg KE
Ann Intern Med; 1991 Aug; 115(3):178-83. PubMed ID: 2058872
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated complications during interferon therapy in hematological patients.
Raanani P; Ben-Bassat I
Acta Haematol; 2002; 107(3):133-44. PubMed ID: 11978934
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis.
Imagawa A; Itoh N; Hanafusa T; Oda Y; Waguri M; Miyagawa J; Kono N; Kuwajima M; Matsuzawa Y
J Clin Endocrinol Metab; 1995 Mar; 80(3):922-6. PubMed ID: 7883851
[TBL] [Abstract][Full Text] [Related]
5. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.
Schilling PJ; Kurzrock R; Kantarjian H; Gutterman JU; Talpaz M
Cancer; 1991 Oct; 68(7):1536-7. PubMed ID: 1893353
[TBL] [Abstract][Full Text] [Related]
6. [Autoimmune phenomena during interferon-alpha therapy for hematopoietic disorders].
Iguchi T; Nishimaki J; Kawakubo K; Shimamoto T; Iwase O; Suzuki A; Kuriyama Y; Ito Y; Tauchi T; Yaguchi M; Miyazawa K; Kimura Y; Ohyashiki K
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1911-6. PubMed ID: 14650958
[TBL] [Abstract][Full Text] [Related]
7. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy.
Custro N; Montalto G; Scafidi V; Soresi M; Gallo S; Tripi S; Notarbartolo A
J Endocrinol Invest; 1997; 20(7):374-80. PubMed ID: 9309534
[TBL] [Abstract][Full Text] [Related]
8. Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature.
Nagayama Y; Ohta K; Tsuruta M; Takeshita A; Kimura H; Hamasaki K; Ashizawa K; Nakata K; Yokoyama N; Nagataki S
Endocr J; 1994 Oct; 41(5):565-72. PubMed ID: 7889118
[TBL] [Abstract][Full Text] [Related]
9. Recombinant alpha-interferons, thyroid irradiation and thyroid disease.
Giles FJ; Worman CP; Jewell AP; Goldstone AH
Acta Haematol; 1991; 85(3):160-3. PubMed ID: 1904180
[TBL] [Abstract][Full Text] [Related]
10. Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons.
Silvestri F; Virgolini L; Mazzolini A; Bertolissi F; Russo D; Fanin R; Baccarani M
Haematologica; 1994; 79(4):367-70. PubMed ID: 7806093
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
[TBL] [Abstract][Full Text] [Related]
12. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders.
Wandl UB; Nagel-Hiemke M; May D; Kreuzfelder E; Kloke O; Kranzhoff M; Seeber S; Niederle N
Clin Immunol Immunopathol; 1992 Oct; 65(1):70-4. PubMed ID: 1382910
[TBL] [Abstract][Full Text] [Related]
13. Thyroid disorders and occurrence of nonorgan-specific autoantibodies (NOSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1).
Hass HG; Klein R; Nehls O; Kaiser S
J Clin Gastroenterol; 2009; 43(5):470-6. PubMed ID: 19247202
[TBL] [Abstract][Full Text] [Related]
14. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study.
Mazziotti G; Sorvillo F; Stornaiuolo G; Rotondi M; Morisco F; Ruberto M; Cioffi M; Amato G; Caporaso N; Gaeta GB; Carella C
J Endocrinol Invest; 2002; 25(7):624-30. PubMed ID: 12150338
[TBL] [Abstract][Full Text] [Related]
15. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis.
Chung YH; Shong YK
Am J Gastroenterol; 1993 Feb; 88(2):244-7. PubMed ID: 8424429
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha and autoimmune thyroid disease.
Prummel MF; Laurberg P
Thyroid; 2003 Jun; 13(6):547-51. PubMed ID: 12930598
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis.
Mayet WJ; Hess G; Gerken G; Rossol S; Voth R; Manns M; Meyer zum Büschenfelde KH
Hepatology; 1989 Jul; 10(1):24-8. PubMed ID: 2737600
[TBL] [Abstract][Full Text] [Related]
18. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C.
Watanabe U; Hashimoto E; Hisamitsu T; Obata H; Hayashi N
Am J Gastroenterol; 1994 Mar; 89(3):399-403. PubMed ID: 8122653
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment.
Rönnblom LE; Alm GV; Oberg K
Acta Oncol; 1991; 30(4):537-40. PubMed ID: 1854511
[TBL] [Abstract][Full Text] [Related]
20. High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-alpha.
Steegmann JL; Requena MJ; Martín-Regueira P; De La Cámara R; Casado F; Salvanés FR; Fernández Rañada JM
Am J Hematol; 2003 Mar; 72(3):170-6. PubMed ID: 12605388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
